BioSpace News Archive

Deals

Avita Medical Half-Year Financial Report for Fiscal 2019

AVITA Medical, a global regenerative medicine company, announced that it filed with the ASX its Appendix 4D – Half-Year Report for the six months ended 31 December 2018.

February 27, 2019
·
42 min read
Policy

FDA Advisory Panel Recommends Waiting for More Data Before Approving Karyopharm’s Selinexor

Shares of Karyopharm Therapeutics are crashing again after an advisory panel from the U.S. Food and Drug Administration recommended delaying potential approval of the company’s experimental multiple myeloma treatment until additional data is available from an ongoing Phase III study.

February 27, 2019
·
3 min read
·
Alex Keown
Business

Novartis and Blackstone Launch Anthos Therapeutics With $250 Million

Blackstone Life Sciences, a private investment firm, along with Novartis, launched Anthos Therapeutics with a $250 million investment. Anthos will be headquartered in Cambridge, Mass.

February 27, 2019
·
3 min read
·
Mark Terry
Deals

Gene Therapy Market Heats up as Sarepta Buys Myonexus for $165 Million

As part of the deal, Sarepta picks up five gene therapy candidates to treat distinct types of LGMD. The original deal was inked in May 2018, when the two companies partnered to develop five gene therapy compounds.

February 27, 2019
·
2 min read
·
Mark Terry
Policy

FDA Unveils New Steps to Address the Opioid Crisis

FDA Commissioner Scott Gottlieb said the agency has changed its approach to the opioid crisis and will take a more aggressive approach on regulatory actions.

February 27, 2019
·
3 min read
·
Alex Keown
Business

Bristol-Myers Squibb Pulls 3 Programs out of CytomX Partnership

Bristol-Myers Squibb and South San Francisco-based CytomX Therapeutics have been collaborating since 2014, a deal that was boosted in 2017 when Bristol-Myers Squibb added up to eight additional targets using CytomX’s Probody platform.

February 27, 2019
·
3 min read
·
Mark Terry
Policy

FDA Issues Refusal to File Letter for Adamis’ Alternative to Cialis

Shares of Adamis Pharmaceuticals are down nearly 5 percent this morning after the company announced late Tuesday that the U.S. Food and Drug Administration rejected its sublingual tadalafil product for erectile dysfunction, an alternative to the blockbuster Cialis.

February 27, 2019
·
2 min read
·
Alex Keown
Policy

Second Lawsuit Alleging Bayer’s Roundup Led to the Development of Cancer Begins

Could a product in a weed killer contribute to the development of a cancer? That is the question a jury will answer as Bayer faces accusations that glyphosate, the active ingredient in its top=selling weed killer Roundup, caused cancer in some individuals who have used the product.

February 27, 2019
·
3 min read
·
Alex Keown
Policy

BioSpace’s Global Biopharma Roundup: Feb. 28

BioSpace gathered together a roundup of global biopharma news from the past week. Bayer and Orion Corporation, Themis Bioscience, Axonics Modulation Technologies, and more are mentioned in this edition.

February 27, 2019
·
4 min read
·
Alex Keown